Author： Coppen Donald
Publisher： Future Medicine
ISSN： 1746-0751
Source： Regenerative Medicine, Vol.5, Iss.2, 2010-03, pp. : 189-195
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Biocompatibles International plc is focused on the development of targeted therapies for a range of indications, including oncology, neurology and cardiology. By delivering the therapy directly to the site of a localized disease numerous benefits can be achieved, including the targeting of a very high therapeutic dose to the required location and reduced systemic toxicity. As part of this strategy the company is now a leader in the field of using locally placed stem cells to make and deliver therapeutically active peptide drugs. The encapsulated cells (CellBeads®), modified to produce a potent anti-apoptotic peptide, CM1, are currently being evaluated in a Phase I/IIa study for the treatment of stroke and in preclinical models of acute myocardial infarction.
Related content
Access to resources
Recommend
Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery, Vol. 7, Iss. 1, 2012-04 ,pp. :
Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine, Vol. 4, Iss. 1, 2014-01 ,pp. :
Thermosensitive polymeric micelles for targeted drug delivery
By Talelli Marina Hennink Wim E
Nanomedicine, Vol. 6, Iss. 7, 2011-09 ,pp. :
AACR meeting highlights new findings on drug resistance, targeted therapies
CANCER, Vol. 119, Iss. 18, 2013-09 ,pp. :